Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine monohydrate in ulcerative colitis
NCT02463305Phase 1Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of creatine in ulcerative colitis (UC) (3 arms), sponsored by University of Colorado Denver. Primary endpoint: Improvement in endoscopic assessment of mucosal inflammation in ulcerative colitis at 8 weeks. Planned start Aug 2022; status: withdrawn.
02
Drugs
creatine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02463305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463305.